Venture capitalist healthcare8/12/2023 Health tech initial public offerings (IPOs) and large-ticket mergers and acquisitions will likely accelerate.Specifically, products and solutions that address well-being and care delivery, along with open, secure data and interoperable platforms, are likely to continue receiving the lion’s share of funding in 2021 and beyond. Health tech innovators focused on developing products that align with Deloitte’s vision for the Future of Health.Many investors, including CVCs, see the postpandemic era as the beginning of a multiyear opportunity rather than a bubble. Venture funding for health tech innovators, at US$14 billion, almost doubled in 2020 compared to 2019 based on Deloitte’s analysis of Rock Health database, and the growth will likely continue unabated in 2021.The Deloitte Center for Health Solutions recently analyzed the latest venture capital funding data from Rock Health’s Digital Health Funding database and interviewed 15 health tech investors-venture capitalists (VC), private equity investors, and corporate venture capitalists (CVCs)-to understand their focus and long-term priorities. Venture capital funding for health tech innovators is often considered an important indicator of their value propositions and potential for long-term success. Health tech innovators were critical to this response. It triggered rapid and large-scale responses, such as a reliance on virtual care delivery, an increased focus on mental health and well-being, and a push for quicker drug and vaccine candidate discoveries. As it did for all industries, the COVID-19 pandemic created an unprecedented crisis for the health care industry. 1 But a year is a long time in this fast-paced sector-and 2020 was an exceptionally long year. We noted that nimble and consumer-focused health tech innovators had begun to fill the gap between current and future needs, enabling a path toward the Future of Health™. Given the strong cultural fit and the complementarity between our organisations, we are convinced that joining forces is a win-win for our investors, our portfolio companies, our LSP colleagues, and the broader European life sciences ecosystem.A year ago, our annual insights report revealed a fast-growing health tech sector. Together with EQT, one of the largest European private equity firms with more than EUR 73 billion in assets under management, LSP can select, develop, and finance these opportunities even better than before. René Kuijten, Managing Partner at LSP, and incoming Partner and Head of EQT Life Sciences, said, “Europe has many attractive life sciences companies. Partner, Head of EQT Life LSP acquired by EQT and renamed to EQT Life Sciences Given the strong cultural fit and the complementarity between our organisations, we are convinced that joining forces is a win-win for our investors, our portfolio companies, our LSP colleagues, and the broader European life sciences ecosystem.” As part of EQT, LSP will be able to continue its strategy and operations as it has done successfully over the past years while leveraging the added value of being part of the EQT family. Henceforth, LSP will be called EQT Life Sciences.ĮQT's acquisition of LSP is driven by the complementarity of investment expertise between the firms as well as significant growth opportunities and scale benefits. The closing of EQT’s acquisition of LSP took place on February 28, 2022. The press release can be found here link. On November 10, 2021, LSP announced that it will join forces with EQT AB (“EQT”), one of the largest private equity firms in Europe and among the top-ten private equity firms globally. X LSP acquired by EQT and renamed to EQT Life Sciences
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |